Sathgen Therapeutics

Sathgen Therapeutics Focuses on Developing and Commercializing Novel Drugs for Diseases with Unmet Needs, Concentrating on Providing Treatments for Difficult-to-Treat Conditions Such as Viral Infections. In Addition to Viral Infections, Sathgen is Also Committed to Advancing Cancer Therapies, with Its Lead Molecule MSP008-22 Set to Enter Phase 1b Clinical Trials to Enhance Efficacy. Their Lead Molecule MSP008-22 Exhibits Broad Antiviral Potential Due to Its Ability to Inhibit Viral Entry and Replication. This NCE Demonstrated Superior Efficacy and Safety Against COVID-19 in Preclinical Development.